[go: up one dir, main page]

SI1534707T1 - Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji - Google Patents

Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji

Info

Publication number
SI1534707T1
SI1534707T1 SI200331101T SI200331101T SI1534707T1 SI 1534707 T1 SI1534707 T1 SI 1534707T1 SI 200331101 T SI200331101 T SI 200331101T SI 200331101 T SI200331101 T SI 200331101T SI 1534707 T1 SI1534707 T1 SI 1534707T1
Authority
SI
Slovenia
Prior art keywords
quinolin
pyrrolo
dihydro
substituted
phosphodiesterase inhibitors
Prior art date
Application number
SI200331101T
Other languages
English (en)
Inventor
Weiqin Johnson Johnson P Jiang
Zhihua Johnson Johnson Ph Sui
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI1534707T1 publication Critical patent/SI1534707T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200331101T 2002-06-19 2003-06-17 Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji SI1534707T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38990402P 2002-06-19 2002-06-19
PCT/US2003/019262 WO2004000842A1 (en) 2002-06-19 2003-06-17 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
EP03761110A EP1534707B9 (en) 2002-06-19 2003-06-17 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
SI1534707T1 true SI1534707T1 (sl) 2008-04-30

Family

ID=30000482

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331101T SI1534707T1 (sl) 2002-06-19 2003-06-17 Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji

Country Status (13)

Country Link
US (1) US6800625B2 (sl)
EP (1) EP1534707B9 (sl)
JP (1) JP4916662B2 (sl)
CN (1) CN100349893C (sl)
AU (2) AU2003243640A1 (sl)
CA (1) CA2490239C (sl)
CY (1) CY1107196T1 (sl)
DE (2) DE60317684D1 (sl)
DK (1) DK1534707T5 (sl)
ES (1) ES2297217T3 (sl)
PT (1) PT1534707E (sl)
SI (1) SI1534707T1 (sl)
WO (1) WO2004000842A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DE102004017435A1 (de) * 2004-04-08 2005-11-03 Bayer Cropscience Ag Annellierte Chinolinderivate
WO2006070385A1 (en) * 2004-12-27 2006-07-06 Council Of Scientific And Industrial Research 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
RU2569899C1 (ru) * 2014-12-16 2015-12-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" Способ получения 6-арил-2-(2-гидроксифенил)-7,15-диокса-2-азатетрацикло[6.5.2.01,5.08,13]пентадец-5-ен-3,4,14-трионов

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2023514A1 (de) 1970-05-14 1971-12-02 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 5,6-gamma-Pyridonderivaten
CH625521A5 (sl) 1976-10-15 1981-09-30 Sandoz Ag
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
CA2189053A1 (en) 1994-04-29 1995-11-09 Shigenori Ohkawa Condensed heterocyclic compounds, their production and use as gnrh antagonists
EP0828731A1 (en) 1995-06-01 1998-03-18 Takeda Chemical Industries, Ltd. TRICYCLIC DIAZEPINES USEFUL AS GnRH RECEPTOR ANTAGONISTS
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2792937B1 (fr) 1999-04-27 2001-08-10 Cemaf NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
JP4484517B2 (ja) 2001-11-14 2010-06-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ホスホジエステラーゼ阻害剤として有用な置換された四環式ピロロキノロン誘導体

Also Published As

Publication number Publication date
CY1107196T1 (el) 2012-11-21
CA2490239A1 (en) 2003-12-31
EP1534707A1 (en) 2005-06-01
DE60317684T2 (de) 2008-10-30
AU2003243640A1 (en) 2004-01-06
EP1534707B9 (en) 2008-11-26
US20040006079A1 (en) 2004-01-08
JP4916662B2 (ja) 2012-04-18
ES2297217T3 (es) 2008-05-01
AU2010202008A1 (en) 2010-06-10
EP1534707B1 (en) 2007-11-21
DK1534707T5 (da) 2010-01-11
WO2004000842A1 (en) 2003-12-31
DE60317684T4 (de) 2011-06-22
DE60317684D1 (de) 2008-01-03
DK1534707T3 (da) 2008-03-25
CA2490239C (en) 2011-05-24
US6800625B2 (en) 2004-10-05
CN100349893C (zh) 2007-11-21
PT1534707E (pt) 2007-12-19
JP2005532370A (ja) 2005-10-27
CN1675210A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
SI1581532T1 (sl) Pirazolo-3,4-b piridinske spojine in njihova uporaba kot zaviralci fosfodiesteraze
HK1088893A1 (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
HK1086012A1 (en) 8-substitued-6,7,8,9-tetrahydropyrimidoÄ1,2-aÜ pyrimidin-4-one derivatives
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
IL175813A0 (en) PYRIDO [2,3-d] PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
HK1066546A1 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
AU2003233519A8 (en) Process for imidazo(4,5-c)pyridin-4-amines
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
HK1066215A1 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
SI1534707T1 (sl) Substituirani derivati 2,4-dihidro-pirolo(3,4-b)kinolin-9-ona, uporabni kot fosfodiesterazni inhibitorji
ZA200408423B (en) Novel tetrahydropyridine derivatives as renin inhibitors.
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU2003211993A1 (en) (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES
EP1610795A4 (en) SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
AU2002309628A1 (en) Carboline derivatives as pde-5 inhibitors
AU2002348365A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
SI1296981T1 (sl) Substituirani pirolopiridinonski derivati, uporabni kot inhibitorji fosfodiesteraze
ZA200306119B (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors.
AU2002317788A1 (en) Imidazotriazines for use as phosphodiesterase inhibitors
SI1549650T1 (sl) Substituirani C-imidazo(1,2-a)piridin-3-il-metilamini
SI1549647T1 (sl) Substituirani C-imidazo(1,2-a)piridin-3-il-metilamini